Abstracts tagged "registry"

Abstract Number: 2619 • ACR Convergence 2025
What Works? A Consolidated Framework for Implementation Research-Guided Exploration of Patient Safety in Rheumatology Practices
Catherine Nasrallah¹, Cherish Wilson², Christine Hariz³, Alicia Hamblin⁴, Cammie Young⁵, gabriela Schmajuk⁶ and Jinoos Yazdany⁴, ¹University of California San Francisco (UCSF), San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³University of California San Francisco (UCSF, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵University of California, San Francisco, Oakland, CA, ⁶University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Despite widespread recognition of persistent patient safety challenges in the U.S. health care system, the development of feasible and scalable solutions has lagged, particularly…
Abstract Number: 1878 • ACR Convergence 2025
Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database
Ashley Orillion¹, Federico Zazzetti², Anna Sheahan³, Clair Blacketer¹, Michel van Speybroeck⁴, Sarah Gasman¹, Reyhan Sonmez⁵, Erika Noss¹, Manuel Ugarte-Gil⁶, Rocío Gamboa-Cárdenas⁷, Víctor Pimentel-Quiroz⁸, Kaleb Michaud⁹, Patti Katz¹⁰, Rangi Kandane-Rathnayake¹¹, Eric Morand¹², Worawit Louthrenoo¹³, Alberta Hoi¹⁴, Yi-Hsing Chen¹⁵, Jiacai Cho¹⁶, Laniyati Hamijoyo¹⁷, Shue Fen Luo¹⁸, Sandra Navarra¹⁹, Mandana Nikpour²⁰, José María Pego-Reigosa²¹, Iñigo Rúa-Figueroa²², Zulema Plaza²³, María Galindo-Izquierdo²⁴, Julia Martínez Barrio²⁵, Jaime Calvo²⁶, Antonio Fernández-Nebro²⁷, Raúl Menor Almagro²⁸, EVA GLORIA TOMERO MURIEL²⁹, Javier Narváez³⁰ and Chetan S. Karyekar³¹, ¹Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ²Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ³Johnson & Johnson, Horsham, PA, USA, Horhsam, PA, ⁴Johnson & Johnson, Beerse, Belgium, Beerse, Belgium, ⁵Capgemini Consulting, Zurich, Switzerland, Zurich, Switzerland, ⁶Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁷Universidad Científica del Sur, Lima, Peru, ⁸Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Perú; Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Perú, Lima, Peru, ⁹University of Nebraska Medical Center, Omaha, NE, ¹⁰UCSF, San Rafael, CA, ¹¹Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ¹²Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ¹³Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, ¹⁴Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ¹⁵Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ¹⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, ¹⁷Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, ¹⁸Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), ¹⁹University of Santo Tomas, Manila, Philippines, ²⁰University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia, ²¹Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ²²Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ²³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ²⁴Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ²⁵Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ²⁶Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ²⁷Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ²⁸Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ²⁹Hospital Universitario de la Princesa, Madrid, Spain, ³⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ³¹Johnson & Johnson, Spring House, PA, USA, Spring House
Background/Purpose: The management of SLE varies worldwide. Current SLE treatment goals focus on preventing flares, controlling disease activity, and preventing organ damage accrual. LupusNet is…
Abstract Number: 1107 • ACR Convergence 2025
Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Laura Cappelli¹, Namrata Singh², Noha Abdel-Wahab³, Anne R. Bass⁴, Tawnie Braaten⁵, Cassandra Calabrese⁶, Nilasha Ghosh⁷, Tamiko Katsumoto⁸, Sang Kim⁹, Minna Kohler¹⁰, Alexa Meara¹¹, Pankti Reid¹², Jeffrey Sparks¹³, Maria Suarez-Almazor¹⁴, Clifton Bingham¹⁵ and Ami Shah¹⁶, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²University of Washington, Bellevue, WA, ³University of Texas MD Anderson Cancer Center, houston, TX, ⁴Hospital for Special Surgery, New York, NY, ⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ⁶Cleveland Clinic Foundation, Cleveland Heights, OH, ⁷Hospital for Special Surgery, New York, NY, ⁸Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ⁹Yale University, Branford, CT, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹¹The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹²University of Chicago Medical Center, Chicago, IL, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴MD Anderson Cancer Center, Houston, TX, ¹⁵Johns Hopkins University, Baltimore, MD, ¹⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Large, multi-center efforts are needed to optimally study rheumatic immune-related adverse events (rh-irAEs) from immune checkpoint inhibitor (ICI) use. We aimed to characterize the…
Abstract Number: 0441 • ACR Convergence 2025
Charting the Course of Worsening: Utilizing Standard Outcomes to Define Worsening for Pathophysiological Insights into RA
Charis Meng¹, Caci Julia², Kelsey Gripp², Deanna Jannat-Khah¹, Yvonne Lee³, Susan J. Bartlett⁴, Clifton Bingham⁵ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Northwestern University, Chicago, IL, ⁴McGill University, Beaconsfield, QC, Canada, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: RA disease worsening contributes to joint damage and cardiovascular disease. While measures of improvement are established in RA, we do not have uniform definitions…
Abstract Number: 2561 • ACR Convergence 2025
Patient-Centricity: The Keystone to Recruitment and Retention of Research Participants for the Lupus Landmark Study and the Success of the Lupus Nexus
Mary Jo Fekete¹, Amonte Davis¹, Courtney Canton², Caroline Donovan³, Carla Menezes⁴, Derek Bennett⁵, Brianna Fitzpatrick⁵, Jamila Jones⁵, Alison Lee⁵, Martin Lewis⁵, Lillian Mendez⁶, Christine Perkins⁷, Dayani Tipple⁸, Ruth Wilson⁹, S. Sam Lim¹⁰, Arezou Khosroshahi¹¹, Alfred Kim¹² and Devon Kelly¹³, ¹Lupus Research Alliance, New York, ²Lupus Therapeutics, Charleston, SC, ³Lupus Therapeutics, Charlottesville, VA, ⁴Lupus Therapeutics, New York, NY, ⁵Patient Advocate, New York, ⁶Patient Advocate, Carteret, NJ, ⁷Patient Advocate, Seattle, Washington, ⁸AstraZeneca, Wilmington, DE, ⁹Patient Advocate, Auburn, IN, ¹⁰Emory University School of Medicine, Atlanta, GA, ¹¹Emory University, Atlanta, GA, ¹²Washington University School of Medicine, St. Louis, MO, ¹³Lupus Research Alliance, New York, NY
Background/Purpose: Community-wide access to highly curated, extensive datasets is critical to advance disease understanding and accelerate precision medicine. To address this unmet need in lupus,…
Abstract Number: 1730 • ACR Convergence 2025
Oral glucocorticoid treatment for checkpoint inhibitor associated inflammatory arthritis do not affect progression free survival: a RADIOS Registry cohort study
Deanna Jannat-Khah¹, Pankti Reid², Maria Suarez-Almazor³, Noha Abdel-Wahab⁴, Jeffrey Sparks⁵, Tawnie Braaten⁶, Cassandra Calabrese⁷, Alexa Meara⁸, Minerva Nong⁹, Kyle Ge¹⁰, Laura Cappelli¹¹, Ami Shah¹², Clifton Bingham¹³ and Anne R. Bass¹, ¹Hospital For Special Surgery, New York, NY, ²University of Chicago Medical Center, Chicago, IL, ³MD Anderson Cancer Center, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, houston, TX, ⁵Brigham and Women's Hospital, Boston, MA, ⁶UNIVERSITY OF UTAH, Salt Lake City, UT, ⁷Cleveland Clinic Foundation, Cleveland Heights, OH, ⁸The Ohio State University Wexner Medical Center, COLUMBUS, OH, ⁹Columbia University, New York, ¹⁰Hospital for Special Surgery, New York, ¹¹Johns Hopkins School of Medicine, Baltimore, MD, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³Johns Hopkins University, Baltimore, MD
Background/Purpose: As immune checkpoint inhibitor (ICI) usage increases for various cancers the prevalence of rheumatologic immune related adverse events (irAEs) also grows. Glucocorticoids are first…
Abstract Number: 1102 • ACR Convergence 2025
Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Julia Barasch¹, Nilasha Ghosh², Deanna Jannat-Khah³, Kyle Ge⁴, Jeffrey Curtis⁵ and Anne R. Bass³, ¹NYP- Weill Cornell, New York, ²Hospital for Special Surgery, New York, NY, ³Hospital For Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: New onset inflammatory arthritis (IA) is reported in 6% of patients who receive immune checkpoint inhibitors (ICI). We previously developed an administrative claims-based algorithm…
Abstract Number: 0433 • ACR Convergence 2025
In-hospital outcomes of patients admitted due to First-Time Pulmonary Embolism with preexisting Rheumatoid Arthritis: A Nationwide Analysis 2016-2022
John Langley¹, Karuna Bista², Clarisse Yapp², Nisha Sapkota³, Shukranta Shrestha² and Sulav Pyakurel¹, ¹Montefiore New Rochelle Hospital, New Rochelle, NY, ²Montefiore New Rochelle Hospital, New Rochelle, ³Interfaith Medical Center, One Brooklyn Health, Brooklyn, NY
Background/Purpose: Although it has been documented that patients with Rheumatoid Arthritis may be at increased risk of Pulmonary Embolism, other inpatient outcomes remain largely unexplored.…
Abstract Number: 2508 • ACR Convergence 2025
Patient-Reported Outcomes in ANCA-Associated Vasculitis: Early Findings from a Prospective Real-World Cohort
Colebrooke Johnson¹, Nora Shepherd², David O'Dea¹, Andrew King², Guy Katz¹, Belen Arevalo Molina¹, Zachary Williams³, Madison Negron⁴, Naomi Patel¹ and Sebastian H Unizony⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Nancy, KY, ⁴Harvard Extension School, Medford, MA, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) imposes a high morbidity burden, both from the disease itself and from treatment-related side effects, often compromising patients’ quality of life…
Abstract Number: 1729 • ACR Convergence 2025
The ERIN Registry: Real-World Data on Rheumatic Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy
Didzis Gailis¹, Fabian T.H. Ullrich¹, Sophia Dombret¹, Rebecca Hasseli-Fräbel², Marc Schmalzing³, Torsten Witte⁴, Mara Oleszowsky⁵, Marcel Müller⁶, Karolina Gente⁷, Uta Kiltz⁸, Christof Specker⁹, Alla Skapenko¹⁰ and Hendrik Schulze-Koops¹⁰, ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, LMU University Hospital, Münich, Bayern, Germany, ²Section of Rheumatology and Clinical Immunology, University Hospital Munster, Münster, Nordrhein-Westfalen, Germany, ³Department of Medicine II, Rheumatology/ Immunology,University Hospital of Wuerzburg, Wuerzburg, Bayern, Germany, ⁴Dept of Rheumatology and Immunology, Hannover, Niedersachsen, Germany, ⁵Private Rheumatology Practice, Köln, Nordrhein-Westfalen, Germany, ⁶The Institute for Medical Information Processing, Biometry, and Epidemiology, LMU University Hospital, München, Bayern, Germany, ⁷Department of Internal Medicine V - Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Baden-Wurttemberg, Germany, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Department of Rheumatology and Clinical Immunology, Kliniken Essen-Mitte, Düsseldorf, Nordrhein-Westfalen, Germany, ¹⁰LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a mainstay of cancer immunotherapy. However, their increasing use has led to more immune-related adverse events (irAEs), including rheumatic…
Abstract Number: 1089 • ACR Convergence 2025
Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Alice Tison¹, Deanna Jannat-Khah², Laura Cappelli³ and Anne R. Bass², ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²Hospital For Special Surgery, New York, NY, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Inflammatory arthritis (IA)- and polymyalgia rheumatica (PMR)-like syndromes occur in about 6% of patients receiving an immune checkpoint inhibitor (ICI) and can worsen quality…
Abstract Number: 0427 • ACR Convergence 2025
Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts
Vilde Øverlien Dåstøl¹, Kristine Løkås Haftorn², Maria Christine Magnus³, Sigrid Hestetun⁴, Siri Eldevik Håberg⁵, Lisa Rider⁶, Karen H. Costenbader⁷, Ida Henriette Caspersen⁸, Sjurdur Frodi Olsen⁹, Ketil Størdal¹⁰ and Helga Sanner¹, ¹Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ³Norwegian Institute of Public Health, Centre for Fertility and Health, Oslo, Norway, ⁴Oslo University Hospital, Department of Rheumatology/University of Oslo, Oslo, Norway, ⁵Norwegian Institute of Public Health, Centre for Fertility and Health/University of Bergen, Oslo, Norway, ⁶National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁷Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ⁸Norwegian Institute of Public Health, Centre for Fertility and Health/Oslo University Hospital, Oslo, Norway, ⁹Statens Serum Institut,Biobank, congenital disorders, and vaccines preparedness/Harvard T.H. Chan School of Public Health, Copenhagen, Denmark, ¹⁰Oslo University Hospital, Department of Pediatric and Adolescent Medicine/University of Oslo, Oslo, Norway
Background/Purpose: Maternal smoking during pregnancy has been associated with a seemingly lower risk of juvenile idiopathic arthritis (JIA) in the child (1), contrasting with smoking’s…
Abstract Number: 2482 • ACR Convergence 2025
Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology
Francesco Bonomi¹, Cosimo Bruni², Silvia Laura Bosello³, Fabio Cacciapaglia⁴, Corrado Campochiaro⁵, Roberto Caporali⁶, Veronica Codullo⁷, Maria Antonietta D'Agostino⁸, Lorenzo Dagna⁹, Rossella De Angelis¹⁰, Giacomo de Luca¹¹, Dilia Giuggioli¹², Serena Guiducci¹³, Florenzo Iannone¹⁴, Francesca Ingegnoli¹⁵, Carlomaurizio Montecucco⁷, Valeria Riccieri¹⁶, Clodoveo Ferri¹⁷, Marco Matucci-Cerinic¹⁸ and Silvia Bellando Randone¹⁹, ¹University Hospital Careggi, Florence, Florence, Toscana, Italy, ²University of Zurich, Zurich, Switzerland, ³Division of Rheumatology and Clinical Immunology - Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy, ⁴Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari & Department of Medicine LUM "G. De Gegnnaro" University, Casamassima (Bari) - Italy, Bari, Italy, ⁵IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁷Policlinico San Matteo, Pavia, Pavia, Italy, ⁸Catholic University of the Sacred Heart, Rome, Rome, Italy, ⁹Ospedale San Raffaele, Milano, Italy, ¹⁰Polytechnic University of Marche, Ancona, Ancona, Italy, ¹¹Vita-Salute San Raffaele University. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, ¹²Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., Modena, Emilia-Romagna, Italy, ¹³Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ¹⁴Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹⁵Clinica Reumatologica, Dipartimento di Reumatologia e Scienze Mediche, ASST Gaetano Pini-CTO, Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza ²⁰²³-²⁰²⁷, Università degli Studi di Milano, Milan, Italy, Milan, Italy, ¹⁶Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy, ¹⁷University of Modena and Reggio Emilia, Modena, Modena, Italy, ¹⁸University San Raffaele Milano, Milano, Milan, Italy, ¹⁹University of Florence, Florence, Italy
Background/Purpose: Gastrointestinal (GI) involvement affects over 80% of patients with systemic sclerosis (SSc), contributing significantly to morbidity and representing the third leading cause of disease-related…
Abstract Number: 1587 • ACR Convergence 2025
Longitudinal Clinical Response to JAK Inhibitors in Systemic Sclerosis: A Real-Life Multicentric Study Across Clinical Domains
Stefano Di Donato¹, JUAN JOSE ALEGRE SANCHO², Anastas Batalov³, Zguro Batalov⁴, Silvia Bellando-Randone⁵, carmela coccia⁶, Marco de Pinto⁷, Dilia Giuggioli⁸ and Michael Hughes⁹, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ³Medical University of Plovdiv, Plovdiv, Bulgaria, ⁴UMHAT Kaspela, Ploudiv, Bulgaria, ⁵University of Florence, Florence, Florence, Italy, ⁶Rheumatology Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy, ⁷Azienda Ospedaliero Universitaria Policlinico di Modena, Parma, Parma, Italy, ⁸Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ⁹Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom
Background/Purpose: JAK inhibitors (JAKi) have shown promising early results in systemic sclerosis (SSc) patients, yet real-world data on their longitudinal effects across different disease domains…
Abstract Number: 1088 • ACR Convergence 2025
Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Alice Tison¹, Deanna Jannat-Khah², Laura Cappelli³ and Anne R. Bass², ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²Hospital For Special Surgery, New York, NY, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: The broad use of immune checkpoint inhibitors (ICIs) in oncology has led to the emergence of ICI-induced inflammatory arthritis (ICI-IA). The aim of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].